Open to Accrual

Studies that are open to accrual

A5369: p24CE Vaccine Study

ACTG A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

Treatment Category:  Treatment Experienced

Study Description
A5369 is a study that will evaluate the safety and effectiveness of a new vaccine in HIV- infected persons. This vaccine, which is called a therapeutic or treatment vaccine, is not meant to prevent HIV infection but rather to improve how the immune system responds to HIV infection.   

A5360: Monitoring SOF-VEL in Treatment Naive, HCV Participants with Active Infection

A5360: A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations who are HCV Treatment Naïve with Evidence of Active HCV Infection: The MINMON Study

A5345: HIV Rebound & Control Biomarkers

Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control during an Intensively Monitored Antiretroviral Pause (IMAP)

Treatment Category: 

Treatment Experienced

Subscribe to RSS - Open to Accrual